Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Selective Estrogen Receptor Degrader (SERDs) Market, Dosage, Price & Clinical Trials Insight 2025

Published by KuicK Research Product code 980135
Published Content info 120 Pages
Delivery time: 1-2 business days
Price
Back to Top
Selective Estrogen Receptor Degrader (SERDs) Market, Dosage, Price & Clinical Trials Insight 2025
Published: January 6, 2021 Content info: 120 Pages
Description

"Selective Estrogen Receptor Degrader (SERDs) Market, Dosage, Price & Clinical Trials Insight 2025" Report Highlights:

  • Global SERD Market Opportunity: > US$ 2 Billion By 2025
  • USA To dominate Global SERD Market
  • SERD In Clinical Trials: > 15 Drugs
  • Detailed Clinical insight on All Drugs in clinical Trials
  • Clinical Pipeline Insight by Company, Country, Indication & Patient Segment
  • Branded & Generic Drug Dosage, Price & Sales Insight
  • 150 Page Report: Commercial & Clinical Opportunity Insight

The research report, "Selective Estrogen Receptor Degrader (SERDs) Market, Dosage, Price & Clinical Trials Insight 2025" provides detailed insight on clinical and non clinical parameters involved in the development and expansion of the global SERD market. In addition to it, the research report also describes the impact of novel drug launches on the other available therapies for breast cancer as well as growth rate of the specific drugs available under the therapy. Other than the market forecast, the research report also highlights the future trends and opportunities that will highly impact the use of expensive drugs for the treatment of breast cancer. Some of the areas that are highlighted in the research report involves the market fragmentation based on the real-world evidence of the therapy at clinical and pre-clinical level.

The global selective estrogen receptor degrader therapy market is witnessed to exceed by a double-digit CAGR rate over the next few years, which will positively impact the other commercially available therapies and cause a notable slowdown in their market growth rate. The major key drivers for the therapy market are estimated to be the US market as well as emerging markets upto some extent, which in the future years will also continue to be the major drivers for the market. The current research and development pipeline for the therapy market is growing at a splendid rate, and the success rate for the market are accelerating at historic level, thus resulting in more launches of potential candidates in the upcoming years. The future novel products approved under selective estrogen receptor degrader therapy market are believed to contribute a large net sales and revenue generation, as the market brand will grow at extensive rate.

The current market is observed to lift the share of the oncology sector to the global pharmaceutical market to new extent, which will continue to increase with time. In addition to it, the overall market at global level has also observed a large influx in the number of market players and government initiatives so that large number of patients could receive benefits from such selective cancer therapy. The highly advanced satisfactory applications and benefits received from the therapy is believed to expand the market to become one standard care for patients suffering from breast cancer.

As per the research conducted for Global selective estrogen receptor degrader therapy market, it is estimated that the therapy when compared with other commercially available therapies can provide maximum potential returns to the breast cancer patients in terms of healthcare benefits as well as to the investors and bio-pharmaceutical companies in terms of total sales and revenue generation. The market due to strong and robust clinical pipeline is also brewing up to become more independently and economically strong. It is observed for the market, that the long-term healthcare benefits available will push the researchers towards conducting more complex clinical research studies in order to generate more applications for the breast cancer patients.

Table of Contents

Table of Contents

1. Introduction to Selective Estrogen Receptor Degraders (SERDs)

  • 1.1 Overview
  • 1.2 Evolution of SERDs

2. Selective Estrogen Receptor Degraders - Mechanism of Action

3. Selective Estrogen Receptor Inhibitors as Combinational Therapy

  • 3.1 SERD with CDK 4/6 Inhibitors
  • 3.2 SERD with PI3K Inhibitors
  • 3.3 SERD with Aromatase Inhibitors
  • 3.4 SERDs with mTOR Inhibitors

4. Role of SERDs in Cancer Treatment

5. Selective Estrogen Receptor Degraders in Breast Cancer

  • 5.1 Impact of SERDs in Breast Cancer Treatment
  • 5.2 Ongoing Research & Development
    • 5.2.1 AZD 9833
    • 5.2.2 Rintodestrant (G1T48)
    • 5.2.3 ZN-c5
    • 5.2.4 Elacestrant (RAD1901)
    • 5.2.5 LSZ 102
    • 5.2.6 OP-1250
    • 5.2.7 LY3484356
    • 5.2.8 GDC-9545 (RG6171)
    • 5.2.9 SHR9549
    • 5.2.10 AZD9496

6. Selective Estrogen Receptor Degrader Market Analysis

  • 6.1 Current Market Scenario
  • 6.2 Impact of COVID-19 on Selective Estrogen Receptor Degrader Market
  • 6.3 Market Opportunity

7. Selective Estrogen Receptor Degrader - Market Trends

  • 7.1 Zentalis Pharma Collaborated with Eli Lily to Evaluate the Combination of SERD with CDK4/6 Inhibitors
  • 7.2 Olema Oncology & Novartis Announces Clinical Collaboration to Evaluate SERD as Combinational Therapy
  • 7.3 New SERD Combinational Therapy Shows Promising Results against HR+/HER2 Negative Breast Cancer
  • 7.4 Radius & Menarini Collaborates for Development & Commercialization of Elacestrant
  • 7.5 SERD Combination Can Target the Neurofibromatosis Gene for Treating Breast Cancer

8. Selective Estrogen Receptor Degrader (SERD) Inhibitors Clinical Trials Overview

  • 8.1 By Company
  • 8.2 By Indication
  • 8.3 By Patient Segment
  • 8.4 By Phase

9. Selective Estrogen Receptor Degrader (SERD) Clinical Trials Insight

  • 9.1 Preclinical
  • 9.2 Phase-I
  • 9.3 Phase-I/II
  • 9.4 Phase-II
  • 9.5 Phase-III

10. Marketed Selective Estrogen Receptor Degrader (SERD) Insight: Fulvestrant

11. Faslodex (Fulvastrant)- Commercially Available Selective Estrogen Receptor Inhibitor Drug

  • 11.1 Approval & Patent Dispute
  • 11.2 Pricing & Dosage Analysis
  • 11.3 Sales Analysis
  • 11.4 Faslodex - Reimbursement Scenario

12. Generic Fulvestrant - Availability & Price Analysis

  • 12.1 Fulviglen
  • 12.2 Fulvenat
  • 12.3 Fulvetraz
  • 12.4 Fuvesterol
  • 12.5 Strantas
  • 12.6 Celvestrant
  • 12.7 Faslomax
  • 12.8 Fasnorm

13. Competitive Landscape

  • 13.1 AsteraZeneca
  • 13.2 Eli Lilly
  • 13.3 G1 Therapeutics
  • 13.4 Novartis
  • 13.5 Olema Oncology
  • 13.6 Radius Therapeutics
  • 13.7 Roche
  • 13.8 Sage Therapeutics
  • 13.9 Zeno Pharma
  • 13.10 Zentalis

List of Figures

  • Figure 1-1: Evolution of SERDs Drugs
  • Figure 2-1: Role of Estrogen Receptor in Tumor Development
  • Figure 2-2: Mechanism of Selective Estrogen Receptor Degraders
  • Figure 2-3: Mechanism of SERDs in Combination with other Cancer Therapeutics
  • Figure 3-1: CDK 4/6 Inhibitors Used in Combination with SERDs
  • Figure 3-2: PI3K Inhibitors Used in Combination with SERDs
  • Figure 3-3: Aromatase Inhibitors Used in Combination with SERDs
  • Figure 4-1: Global - Breast Cancer Cases by Nature of Estrogen Receptor (%), 2020
  • Figure 4-2: Role of SERDs in Cancer Management
  • Figure 5-1: Global - Newly Diagnosed Cases & Deaths related to Breast Cancer (Million), 2020
  • Figure 5-2: Global - Breast Cancer Cases by Type (Million), 2020
  • Figure 5-3: Investigational SERDs Candidates & Their Manufacturers
  • Figure 5-4: SERENA-2 Trial - Study Initiation & Expected Completion Year For Primary Breast Cancer
  • Figure 5-5: SERENA-2 Trial - Study Initiation & Expected Completion Year for Advanced Breast Cancer
  • Figure 5-6: SERENA-1 Trial - Study Initiation & Expected Completion Year
  • Figure 5-7: AZD9833 Japan Trial - Study Initiation & Expected Completion Year
  • Figure 5-8: Rintodestrant Phase I Trial - Study Initiation & Expected Completion Year
  • Figure 5-9: ZN-c5 Monotherapy Trial - Study Initiation & Expected Completion Year
  • Figure 5-10: ZN-c5/Abemaciclib Combination Trial- Study Initiation & Expected Completion Year
  • Figure 5-11: ZN-c5/ Palbociclib Trial- Study Initiation & Expected Completion Year
  • Figure 5-12: Elacestrant Phase 3 Trial- Study Initiation & Expected Completion Year
  • Figure 5-13: Elacestrant - Study Initiation & Completion Year
  • Figure 5-14: LSZ102 Phase I/II Trial- Study Initiation & Completion Year
  • Figure 5-15: OP-1250 Phase I/II Trial - Study Initiation & Completion Year
  • Figure 5-16: EMBER-2 Trial - Study Initiation & Expected Completion Year
  • Figure 5-17: LY3484356 Phase I Trial - Study Initiation & Expected Completion Year
  • Figure 5-18: GDC-9545 Phase I Trial- Study Initiation & Expected Completion Year
  • Figure 5-19: GDC-9545/Fulvestrant Combinational Trial - Study Initiation & Expected Completion Year
  • Figure 5-20: SHR 9549 Phase I Trial - Study Initiation & Completion Year
  • Figure 6-1: Global - SERD Market Size (US$ Million), 2016 - 2020
  • Figure 6-2: Global - SERD Market Size by Type of Product (US$ Million), 2019
  • Figure 6-3: Global - SERD Market Size by Type of Product (%), 2019
  • Figure 6-4: Global - Number of Pharmaceutical Organization Impacted by COVID-19 by Intensity, 2020
  • Figure 6-5: Global - Number of Pharmaceutical Organization Impacted by COVID-19 by Intensity (%), 2020
  • Figure 6-6: Global - Estimated Breast Cancer Cases (Million), 2020, 2025 & 2030
  • Figure 6-7: Global - Estimated Breast Cancer Cases (Million), 2020, 2025 & 2030
  • Figure 6-8: Global - Estimated ER Positive Breast Cancer Cases (Million), 2020, 2025 & 2030
  • Figure 6-9: Global - SERD Market Opportunity (US$ Billion), 2020 - 2025
  • Figure 6-10: US - SERD Market Opportunity (US$ Million), 2020 - 2025
  • Figure 6-11: Europe - SERD Market Opportunity (US$ Million), 2020 - 2025
  • Figure 8-1: SERD - Clinical Trials by Company (Number of Drugs), 2020 - 2025
  • Figure 8-2: SERD - Clinical Trials by Indication (Number of Drugs), 2020 - 2025
  • Figure 8-3: SERD - Clinical Trials by Patient Segment (Number of Drugs), 2020 - 2025
  • Figure 8-4: SERD - Clinical Trials by Phase (Number of Drugs), 2020 - 2025
  • Figure 11-1: Faslodex - FDA Approval Year by Type of Breast Cancer
  • Figure 11-2: Faslodex - FDA Approval Year & First Generic Approval Year
  • Figure 11-3: Faslodex - Patent Issue & Expiration Year
  • Figure 11-4: Faslodex - Price for 10 ml & Price per ml of Intramuscular Injection (US$), January'2021
  • Figure 11-5: Faslodex - Recommended & Reduced Dose (mg)
  • Figure 11-6: Faslodex - Number of Doses by Treatment Phase
  • Figure 11-7: Faslodex - Cost For First & Subsequent Treatment Cycle (US$)
  • Figure 11-8: Global - Faslodex Annual Sales Value (US$ Million), 2016 - 2019
  • Figure 11-9: Global - Faslodex Annual Sales Values (US$ Million), 2002 - 2015
  • Figure 11-10: Global - Faslodex Quarterly Sales Value (US$ Million), 2018 & 2019
  • Figure 11-11: US - Faslodex Annual Sales Value (US$ Million), 2017 - 2019
  • Figure 11-12: Europe - Faslodex Annual Sales Value (US$ Million), 2017 - 2019
  • Figure 11-13: Global - Faslodex Annual Sales Value by Region (US$ Million), 2019
  • Figure 11-14: Global - Faslodex Annual Sales Value by Region (%), 2019
  • Figure 11-15: Global - Faslodex Quarterly Sales Value (US$ Million), Q1 - Q3, 2020
  • Figure 11-16: Global - Faslodex 9 Month Sales Value by Region (US$ Million), 2020
  • Figure 11-17: Global - Faslodex 9 Month Sales Value by Region (%), 2019
  • Figure 11-18: US - Faslodex Quarterly Sales Value (US$ Million), Q1 - Q3, 2020
  • Figure 11-19: Europe - Faslodex Quarterly Sales Value (US$ Million), Q1 - Q3, 2020
  • Figure 11-20: US - Typical Co-Pay Range of Branded & Generic Fulvestrant (US$), January'2021
  • Figure 12-1: Fulviglen - Price for a Supply of 3 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-2: Fulviglen - Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-3: Fulviglen - Price for a Supply of 9 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-4: Fulvenat - Price for a Supply of 2 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-5: Fulvenat - Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-6: Fulvenat - Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-7: Fulvetraz - Price for a Supply of 2 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-8: Fulvetraz - Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-9: Fulvetraz - Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-10: Fuvesterol - Price for a Supply of 2 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-11: Fuvesterol - Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-12: Fuvesterol - Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-13: Strantas - Price for a Supply of 2 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-14: Strantas - Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-15: Strantas - Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-16: Celvestrant - Price for a Supply of 2 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-17: Celvestrant - Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-18: Celvestrant - Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-19: Faslomax - Price for a Supply of 2 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-20: Faslomax - Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-21: Faslomax - Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-22: Fasnorm - Price for a Supply of 2 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-23: Fasnorm - Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
  • Figure 12-24: Fasnorm - Price for a Supply of 6 Injection & Price per unit of 250mg Intramuscular Injection (US$), January'2021
Back to Top